camptothecin has been researched along with 10,11-methylenedioxy-20-camptothecin in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (58.33) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Besterman, JM; Emerson, DL; Evans, MG; Lackey, K; Leitner, PL; Luzzio, MJ; McIntyre, G; Morton, B; Myers, PL; Peel, M | 1 |
| Besterman, JM; Leitner, P; Manikumar, G; Moore, L; Nicholas, AW; Tele, C; Truesdale, A; Wall, ME; Wani, MC | 1 |
| Fan, Y; Kohn, KW; Pommier, Y; Shi, LM; Weinstein, JN | 1 |
| Bearss, D; Manikumar, G; Von Hoff, DD; Wadkins, RM; Wall, ME; Wani, MC | 2 |
| Bertrand, R; Goldman, J; Kerrigan, D; Kohn, KW; Nieves-Neira, W; O'Connor, PM; Pommier, Y | 1 |
| Bertrand, R; Kerrigan, D; Kohn, KW; O'Connor, PM; Pommier, Y | 1 |
| Malspeis, L; Supko, JG | 1 |
| Mangold, G; Manikumar, G; Marty, J; Potter, PM; Vladu, B; Von Hoff, DD; Wadkins, RM; Wall, ME; Wani, MC; Weitman, S | 1 |
| Collins, JR; Jerina, DM; Kroth, H; Laco, GS; Luke, BT; Pommier, Y; Sayer, JM | 1 |
| Alderson, LM; Amundson, E; Brem, H; Colvin, M; Sampath, P; Tyler, BM; Wall, ME; Wani, MC; Weingart, JD | 1 |
| Chen, X; Cheng, X; Gao, T; Gao, Y; Kong, M; Li, P; Wang, J; Wang, Z | 1 |
12 other study(ies) available for camptothecin and 10,11-methylenedioxy-20-camptothecin
| Article | Year |
|---|---|
Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Survival; Female; Humans; Mice; Solubility; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Water | 1995 |
Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs.
Topics: Animals; Antineoplastic Agents; Camptothecin; Female; Humans; Leukemia L1210; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred DBA; Molecular Conformation; Molecular Structure; Plants, Medicinal; Stereoisomerism; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1993 |
Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
Topics: Amino Acid Substitution; Antineoplastic Agents; Binding Sites; Camptothecin; DNA; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Enzyme Inhibitors; Hydrogen Bonding; Ligands; Models, Molecular; Molecular Conformation; Mutation; Protein Conformation; Stereoisomerism; Structure-Activity Relationship; Thermodynamics; Topoisomerase I Inhibitors | 1998 |
Camptothecin analogs with bulky, hydrophobic substituents at the 7-position via a Grignard reaction.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Ketones; Structure-Activity Relationship; Topoisomerase I Inhibitors | 2004 |
S-phase population analysis does not correlate with the cytotoxicity of camptothecin and 10,11-methylenedioxycamptothecin in human colon carcinoma HT-29 cells.
Topics: Animals; Aphidicolin; Camptothecin; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Diterpenes; DNA Polymerase II; DNA Replication; DNA, Neoplasm; Humans; Molecular Structure; S Phase; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1991 |
10,11-Methylenedioxycamptothecin, a topoisomerase I inhibitor of increased potency: DNA damage and correlation to cytotoxicity in human colon carcinoma (HT-29) cells.
Topics: Camptothecin; Colonic Neoplasms; Colony-Forming Units Assay; DNA Damage; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Topoisomerase I Inhibitors | 1990 |
Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in mice.
Topics: Animals; Camptothecin; Male; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Structure-Activity Relationship; Tissue Distribution | 1993 |
Water soluble 20(S)-glycinate esters of 10,11-methylenedioxycamptothecins are highly active against human breast cancer xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cholinesterase Inhibitors; Drug Screening Assays, Antitumor; Esters; Female; Glycine; Humans; Infant, Newborn; Irinotecan; Mice; Mice, Nude; Molecular Structure; Neoplasm Transplantation; Solubility; Structure-Activity Relationship; Tumor Cells, Cultured | 1999 |
Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model.
Topics: Binding Sites; Binding, Competitive; Camptothecin; DNA; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Hydrogen Bonding; Irinotecan; Models, Molecular; Molecular Conformation; Nucleic Acid Heteroduplexes; Structure-Activity Relationship; Substrate Specificity; Thermodynamics; Topoisomerase I Inhibitors | 2002 |
Camptothecin analogs in malignant gliomas: comparative analysis and characterization.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Camptothecin; Carmustine; Cell Division; Drug Screening Assays, Antitumor; Glioma; Humans; Rats; Tumor Cells, Cultured | 2003 |
Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I.
Topics: Animals; Camptothecin; Cell Line, Tumor; DNA; DNA Topoisomerases, Type I; Female; HeLa Cells; HT29 Cells; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Mice; Mice, SCID; Models, Molecular; Structure-Activity Relationship; Water | 2004 |
Transdermal delivery of 10,11-methylenedioxycamptothecin by hyaluronic acid based nanoemulsion for inhibition of keloid fibroblast.
Topics: Animals; Camptothecin; Cell Cycle; Emulsions; Fibroblasts; Gene Expression Regulation; Humans; Hyaluronic Acid; Keloid; Male; Mitosis; Nanostructures; Rats, Wistar; Skin; Tissue Distribution | 2014 |